Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next?

Key Points

• Valneva shares surged on unusually heavy trading volume, with about 2.1 million shares changing hands—up 3,213% from the prior session—and the stock trading near $7.13 versus a $5.65 close.
• The European Medicines Agency validated Pfizer and Valneva’s marketing application for their six-valent Lyme disease vaccine candidate, beginning the formal review. Pfizer expects key decisions within roughly 12 months, creating a potential major growth catalyst.
• Valneva reaffirmed 2026 revenue guidance of approximately €145 million–€160 million, but second-quarter results missed expectations, with a $0.40 per-share loss and $39.37 million in revenue; analysts’ overall rating remains Hold.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) saw unusually-high trading volume on Friday . Approximately 2,094,686 shares were traded during mid-day trading, an increase of 3,213% from the previous session's volume of 63,226 shares.The stock last traded at $7.1310 and had previously closed at $5.65.

Valneva News Summary

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s marketing authorization application for their six-valent Lyme disease vaccine candidate, PF-07307405. Validation begins the EMA’s formal review and represents an important regulatory milestone, although it is not an approval. Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Management said Pfizer expects key Lyme vaccine decisions within roughly 12 months, giving investors a clearer timeline for a potentially significant future growth driver. The program is being developed with Pfizer, which could provide Valneva with milestone and commercial opportunities. Valneva outlines 2026 revenue guidance while Pfizer targets Lyme decisions
• Positive Sentiment: Valneva reaffirmed its 2026 revenue outlook of approximately €145 million to €160 million, indicating continued confidence in its commercial vaccine portfolio despite near-term losses. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
• Neutral Sentiment: TD Cowen initiated research coverage on Valneva. The coverage may improve institutional visibility, but the available report does not specify an investment rating or price target. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Second-quarter results missed expectations: Valneva reported a $0.40 per-share loss versus the $0.23 consensus loss, while revenue of $39.37 million came below the $43.15 million estimate. The company remains deeply unprofitable, increasing the importance of successful product sales and the Lyme vaccine program. Valneva quarterly earnings results

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on VALN. Guggenheim set a $11.00 target price on Valneva in a research note on Thursday, April 16th. The Goldman Sachs Group downgraded shares of Valneva from a "neutral" rating to a "sell" rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Wall Street Zen upgraded shares of Valneva from a "strong sell" rating to a "sell" rating in a research note on Monday, June 1st. TD Cowen assumed coverage on shares of Valneva in a research report on Tuesday. They set a "buy" rating and a $12.00 target price for the company. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Valneva in a research note on Thursday, June 18th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $11.98.

Valneva Price Performance

The stock has a market cap of $664.23 million, a P/E ratio of -3.74 and a beta of 1.77. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The business's 50-day simple moving average is $5.21 and its two-hundred day simple moving average is $6.92.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17). The business had revenue of $39.37 million during the quarter, compared to the consensus estimate of $43.15 million. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. Sell-side analysts expect that Valneva SE Sponsored ADR will post -1 EPS for the current year.

Institutional Investors Weigh In On Valneva

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marex Group plc bought a new position in shares of Valneva in the second quarter worth $64,000. XTX Topco Ltd bought a new stake in shares of Valneva during the 4th quarter valued at $94,000. JPMorgan Chase & Co. bought a new stake in shares of Valneva during the 3rd quarter valued at $124,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Valneva during the 4th quarter worth about $44,000. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva's research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source